Fentanyl test strips have become a small object carrying a large policy argument. To some officials, they are a practical way to reduce the chance of an unexpected overdose. To critics, distributing them looks like an admission that drug use cannot be stopped—or worse, a signal that it is being accepted. That debate often produces more heat than clarity.
The research supports a narrower and more useful conclusion. Fentanyl test strips are not a guarantee of safety, and the evidence does not justify claiming that they independently prevent every overdose. But they are a feasible point-of-consumption intervention associated with behaviors that reduce risk. Their strongest policy case is therefore not that a strip solves the illicit drug market. It is that people make safer decisions when they receive actionable information without having to pass through a punitive system first.
The Policy Question Behind a Small Strip
The question is not whether a test strip makes an unpredictable drug supply safe. It cannot. The question is whether information about that supply can change what happens next.
That distinction matters because illicit markets are information-poor and volatile. A person may know what they intended to buy while not knowing its actual contents, potency, or whether a batch has changed. Fentanyl can appear in drugs sold as other substances, and a product sold under the same name may not be chemically consistent from one purchase to the next. In that setting, a low-cost test is a form of risk communication: imperfect, but potentially consequential.
The Centers for Disease Control and Prevention describes fentanyl test strips as one way to detect fentanyl in drug products, while also emphasizing that a negative result does not prove that a product is safe. That combination—useful information plus explicit uncertainty—is the appropriate starting point for policy.
What the Research Can Establish
The most important recent evidence comes from a multisite observational cohort study published by Rachel Vickers-Smith and colleagues in 2025. The researchers followed 732 people who use drugs in Kentucky, New York, and Ohio. Participants who reported using fentanyl test strips at baseline were more likely, during the 28-day follow-up, to report a range of overdose-risk-reduction behaviors than participants who did not report baseline use.
The study does not show that test strips caused those behaviors. It was observational, not a randomized experiment, and people who choose test strips may already be more connected to harm-reduction services or more motivated to reduce risk. The authors also found no statistically clear reduction in nonfatal overdose during that short follow-up. Those are not minor caveats; they define what can responsibly be claimed.
At the same time, limitations do not make the finding meaningless. The result is consistent with a broader evidence base summarized in a 2024 scoping review by Kutscher and colleagues. That review found strong evidence for the feasibility, acceptability, sensitivity, and specificity of fentanyl test strips, but much less evidence for their ultimate effect on overdose outcomes. In other words, the intervention is usable and potentially behavior-shaping; the field still needs stronger designs to estimate its mortality effect.
Laboratory research adds another reason to avoid overstatement. McDonald and colleagues found that commercial strips can detect fentanyl and some analogues, but performance varies across manufacturing lots and testing conditions. A test can be useful without being infallible. Public-health guidance should therefore pair strips with clear instructions, naloxone, not using alone, and rapid access to medical and treatment services.
Why Behavior Change Matters
A narrow evaluation asks: did the strip prevent an overdose? That outcome matters, but it is rare, difficult to measure, and shaped by many conditions outside the intervention. A better evaluation also asks what the information enabled.
Research participants have reported using smaller amounts, taking a tester shot, using more slowly, not using the substance, or making sure someone was present with naloxone after a positive result. These are not equivalent choices, and none should be treated as a guarantee. Their importance is that they create additional opportunities for survival in a setting where a single mistake can be fatal.
This is the central harm-reduction insight: policy can reduce injury without requiring abstinence as a precondition for assistance. That is not an argument against treatment or recovery. It is an argument for keeping people alive and connected long enough for treatment, recovery, and other forms of support to remain possible.
For criminal justice policy, the implication is equally important. If people fear that possessing a test strip, calling for help, or seeking harm-reduction supplies could expose them to punishment, the legal system has converted safety information into a liability. Decriminalizing or explicitly protecting drug-checking supplies is therefore not symbolic. It changes the expected cost of taking a precaution.
The Limits of a Positive or Negative Result
A positive result indicates that fentanyl was detected under the test conditions. It does not measure dose, potency, or uniform distribution in the entire sample. A negative result indicates that the strip did not detect fentanyl above its detection threshold in the tested preparation. It does not certify that the substance is free of fentanyl, other synthetic opioids, benzodiazepines, xylazine, or other hazards.
That uncertainty should be communicated plainly rather than used to dismiss the technology. No smoke alarm detects every possible fire, but that does not make smoke alarms useless. It means users need to understand what the device can and cannot tell them—and policymakers need to fund a broader safety system around it.
The same caution applies to the phrase “fentanyl test strip.” Product quality, sample preparation, and local drug markets differ. Organizations distributing strips should use validated products, provide practical instructions, explain false negatives, and collect feedback about unexpected results. The strip is one layer of risk reduction, not a substitute for naloxone or emergency response.
From Individual Tool to Market Intelligence
Drug checking can also produce knowledge that is valuable beyond the individual transaction. Aggregated, privacy-protective reports of positive tests can help harm-reduction organizations identify changes in local supply and communicate warnings quickly. This does not turn test strips into a surveillance system; it turns distributed observations into public-health intelligence without requiring police access to individual-level data.
That distinction is crucial. A community warning system should protect the people whose experiences generate the information. If testing data are repurposed for enforcement, people may stop using the service, and the information needed for prevention disappears. The governance question is therefore inseparable from the technical one: who owns the data, who can access it, and whose safety is the system designed to serve?
What Better Policy Would Look Like
Evidence-informed policy would treat fentanyl test strips as one component of a layered response:
- remove drug-paraphernalia penalties and other legal barriers to possession and distribution;
- distribute strips through syringe-service programs, outreach teams, pharmacies, emergency departments, and peer-led organizations;
- pair testing with naloxone, overdose education, treatment navigation, and nonjudgmental medical care;
- fund independent evaluation, including studies that distinguish opioid use from nonopioid use and assess different local drug markets;
- report uncertainty honestly, including false negatives and substances that fentanyl strips cannot detect; and
- keep individual testing information outside routine policing and immigration enforcement.
This approach avoids two opposite errors. The first is technological optimism: pretending a strip can make an unstable market predictable. The second is punitive realism: concluding that because the tool is imperfect, it should be withheld. The evidence supports neither. It supports a modest intervention embedded in a serious public-health infrastructure.
Conclusion
Fentanyl test strips do not resolve the structural causes of overdose, and current research cannot justify a simple causal claim that they reduce mortality on their own. What the evidence does show is more practical: strips are acceptable and feasible, they can reveal information that consumers otherwise lack, and their use is associated with a broader set of risk-reduction behaviors.
The policy lesson is not that testing makes drug use safe. It is that people deserve access to information that may help them survive an unsafe market. A criminal justice system committed to reducing harm should not punish that effort. It should remove barriers, protect trust, and make the next safer choice easier.
References
- Centers for Disease Control and Prevention. (2024). Fentanyl: Overdose prevention. https://www.cdc.gov/overdose-prevention/about/fentanyl.html
- Kutscher, E., et al. (2024). Fentanyl test strips for harm reduction: A scoping review. Journal of Addiction Medicine, 18(6), 587–596. https://doi.org/10.1097/ADM.0000000000001321
- McDonald, R., et al. (2024). Testing the test strips: Laboratory performance of fentanyl test strips. Harm Reduction Journal, 21, 14. https://doi.org/10.1186/s12954-023-00921-8
- Vickers-Smith, R. A., et al. (2025). Fentanyl test strip use and overdose risk reduction behaviors among people who use drugs. JAMA Network Open, 8(5), e2510077. https://doi.org/10.1001/jamanetworkopen.2025.10077